Ascendis Pharma Reports Second Quarter 2024 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/5/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Tanker struck by projectile in Strait of Hormuz
Oppenheimer Upgrades Ascendis Pharma (ASND) to Outperform
September 5, 2024 6:54 AM EDTOppenheimer analyst Leland Gershell upgraded Ascendis Pharma (NASDAQ: ASND) from Perform to Outperform with a price target of $180.00.
The analyst comments "We upgrade ASND to Outperform (from Perform) and assign a $180 PT ahead of 1) Yorvipath's US launch for hypoparathyroidism (to commence by 1Q25)... More
Ascendis Pharma (ASND) PT Lowered to $174 at Jefferies
September 4, 2024 5:18 AM EDTJefferies analyst Kelly Shi lowered the price target on Ascendis Pharma (NASDAQ: ASND) to $174.00 (from $196.00) while maintaining a Buy rating.
The analyst comments "Skytrofa experienced a revenue growth reversal in Q2 (26M; -58% Q/Q; -25% YoY) on an unexpected net price... More
Ascendis Pharma (ASND) PT Lowered to $180 at Goldman Sachs
September 4, 2024 5:06 AM EDTGoldman Sachs analyst Paul Choi lowered the price target on Ascendis Pharma (NASDAQ: ASND) to $180.00 (from $195.00) while maintaining a Buy rating.
The analyst comments "Miss for Skytrofa on the back of insurance contract resets and significant price pressure; focus remains on upcoming US... More
Ascendis Pharma (ASND) PT Lowered to $178 at Citi
September 4, 2024 4:57 AM EDTCiti analyst David Lebowitz lowered the price target on Ascendis Pharma (NASDAQ: ASND) to $178.00 (from $193.00) while maintaining a Buy rating.
The analyst comments "Ascendis reported 2Q24 financial results, missing Street estimates on topline revenue and GAAP EPS as the company made significant accounting... More
